Urgent.News

What's breaking now, across thousands of outlets.

AI

Swiss neurotech Indivi acquires Cogitat to advance AI-powered brain monitoring

Neurotech company Indivi has acquired Cogitat, an Imperial College London spin-out developing cutting-edge deep learning models that decode cognitive function from EEG brain signals. Indivi is a neu...

Swiss neurotech Indivi acquires Cogitat to advance AI-powered brain monitoring

Swiss neurotech firm Indivi has acquired Cogitat, a London-based spin-out specializing in deep learning models that translate EEG brain signals into cognitive function. Based in Basel, Switzerland, with offices in Spain and Massachusetts, Indivi uses precision measurement and analytics to aid biopharmaceutical companies in designing early-stage trials and detecting treatment effects more confidently.

Its current platform includes smartphone-based assessments for motor and cognitive functions, focusing on Parkinson's disease, neuromuscular diseases, multiple sclerosis, and Alzheimer's disease and related dementias.

Cogitat's foundation model, NeuroRVQ, decodes EEG brainwaves in a way that works on any individual and any device, aiming to decode brain activity as effectively as large language models decode language. CEO and Founder of Indivi, Guilhem Dupont, highlighted the complexity of the brain and the model's potential to provide drug developers with earlier data on how treatments work for brain conditions.

Cogitat's CEO and Founder, Allan Ponniah, emphasized that every brain is unique and speaks its own language, and their model works across all these unique languages without individual training to detect subtle changes in brain activity that were previously hard to identify.

Indivi will collaborate with Cogitat's skilled AI and scientific team to further develop the foundation model, which captures fine details in brain signals that other models might overlook. This, combined with Indivi's advanced precision measurement, will enhance the detection of experimental Alzheimer's treatments' effects, strengthening research and development across the life sciences.

In the future, the model could power new healthcare and consumer applications by converting EEG brain data into actionable insights. Indivi's next step involves using NeuroRVQ's AI-driven approach to improve how scientists and biopharma companies measure treatment efficacy for brain diseases like Alzheimer's, potentially accelerating clinical trials and bringing effective treatments to market sooner.

Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at tech.eu →

More in AI

More from Tuesday 17 November →